The Recall: Quidel’s Cardiac Testing Panels

In a recent announcement, the U.S. Food and Drug Administration (FDA) has issued a Class I recall—the most severe level—on Quidel Cardiovascular’s Triage Cardiac Panels. The recall was prompted due to the risk of false negative results in troponin levels, a critical biomarker in diagnosing myocardial infarction, commonly known as a heart attack.

Implications: Diagnosis Delays and Missed Heart Attacks

A false negative in troponin testing could lead to a potentially fatal delayed or missed diagnosis of myocardial infarction. This risk is particularly severe for individuals who experience a silent myocardial infarction with no other symptoms, those with unusual or atypical symptoms, and those suffering from a non-ST-segment elevation myocardial infarction (NSTEMI).

According to the FDA, continued usage of these panels without appropriate action could result in serious injuries or death, underscoring the urgent need for recall and remediation.

Figures: The Impact of the Recall

As of the recall’s initiation by Quidel on May 25, 2023, it affects 7,799 devices distributed across the United States since November 1, 2022. Quidel has received 41 complaints regarding these panels, with thankfully no injuries or deaths reported.

Actions Taken: Quidel’s Response

In response to the issue, Quidel has sent out Urgent Product Correction Notifications and recommended immediate discontinuation of the product. Alternate methods or testing sites are encouraged. In cases where these are not available, the firm has proposed a comprehensive plan to mitigate the patient impact and minimize risk, including flagging all negative results as possibly inaccurate and advising serial sampling.

Addressing the Issue

This recall serves as a crucial reminder for healthcare personnel and patients alike about the importance of accuracy and reliability in medical diagnostics. With the rising utilization of point-of-care testing in cardiovascular disease management, recalls like these underscore the need for rigorous quality assurance mechanisms. For questions or concerns, Quidel has made available its contact line and encourages users to reach out to their local Quidel Technical Solutions Center.

Additional information and ongoing updates can be found in the FDA’s Medical Device Recall Database.